Epygenix — Biomedical Watch V2

Traitements3programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Clemizole HClThis is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).	Épilepsie	Phase 3	À vérifier	United States, China, Italy, Poland, Romania, Serbia, Spain	À vérifier
Clemizole HClThis is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).	Épilepsie	Phase 3	À vérifier	United States, Argentina, Brazil, Canada, Georgia, Hungary, India, Poland, Spain, United Kingdom	À vérifier
Clemizole HClThis is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).	Épilepsie	Phase 3	À vérifier	United States, China, Italy, Poland, Romania, Serbia, Spain	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Clemizole HCl	Épilepsie	Phase 3	NCT05066217	An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome	RECRUITING
Clemizole HCl	Épilepsie	Phase 3	NCT04462770	ARGUS — A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.